BioNTech's revenues plummeted 78.1% in the first half of 2024, down to €316.3 million, due to decreased demand for Covid-19 vaccines and a seasonal sales lull....
A week ago, BioNTech presented its billing forecasts for 2024, with the aim of reaching €3 billion. The figure represents a significant decrease in value compared...